What's happened
GLP-1 medications are being increasingly prescribed off-label to children aged 8–11 in the US, despite no FDA approval for under-12s. A NYU Langone study shows a dramatic rise in June 2026, while experts warn about long-term effects and the broader obesity crisis.
What's behind the headline?
Critical Analysis
- The NYU Langone data highlights a surge in GLP-1 prescriptions among 8–11-year-olds, even though no FDA approval exists for this age group. This underscores a gap between clinical practice and regulatory guidelines.
- The debate centers on balancing obesity treatment with potential developmental risks. Experts warn about growth, bone health, and puberty, while others argue GLP-1s are a tool to curb a rising obesity epidemic.
- The broader story points to systemic factors: access to health care, availability of alternatives (lifestyle programs), and the ethics of off-label prescribing for children.
- Readers should assess long-term data, weigh immediate obesity-related risks, and watch for updates on safety studies in adolescents.
How we got here
Rising obesity in America has driven demand for GLP-1 therapies like Ozempic and Wegovy. While approved for adults (and certain conditions), off-label pediatric use has grown, raising questions about long-term safety in developing bodies and the ethical balance between weight management and child health.
Our analysis
- New York Post reports on NYU Langone study showing a 310x increase in GLP-1 prescriptions for 8–11-year-olds from 2019 to June 2026. - Independent notes potential anti-aging and metabolic benefits of GLP-1s in animals and humans, underscoring expanding use. - The Guardian highlights the global rise of dementia and its preventability, contextualizing chronic disease management. - The New York Times Business discusses gene-editing advances as a separate but related frontier in medicine.
Go deeper
- Will regulators issue new guidance on pediatric off-label GLP-1 use?
- What are safer, non-pharmacological options for childhood obesity?
- How will long-term data on adolescent GLP-1 use shape practice?
More on these topics
-
European Society of Cardiology - Non-profit
The European Society of Cardiology is a non-profit knowledge-based professional association that facilitates the improvement and harmonisation of standards of diagnosis and treatment of cardiovascular diseases.